<産業資料/調査レポートの題名> 2022年7月19日

神経変性疾患治療薬の世界市場2018-2022


◆英文タイトル:Global Neurodegenerative Diseases Therapeutics Market 2018 -2022

PART 01: EXECUTIVE SUMMARY
PART 02: SCOPE OF THE REPORT
PART 03: RESEARCH METHODOLOGY
PART 04: MARKET LANDSCAPE
• Market ecosystem
• Market characteristics
• Market segmentation analysis
PART 05: PIPELINE ANALYSIS
• Pipeline analysis
PART 06: MARKET SIZING
• Market definition
• Market sizing 2017
• Market size and forecast 2017-2022
PART 07: FIVE FORCES ANALYSIS
• Bargaining power of buyers
• Bargaining power of suppliers
• Threat of new entrants
• Threat of substitutes
• Threat of rivalry
• Market condition
PART 08: MARKET SEGMENTATION BY INDICATION
• Segmentation by indication
• Comparison by indication
• Multiple sclerosis – Market size and forecast 2017-2022
• Others – Market size and forecast 2017-2022
• Alzheimer’s disease – Market size and forecast 2017-2022
• Parkinson’s disease – Market size and forecast 2017-2022
• Huntington’s disease – Market size and forecast 2017-2022
• Market opportunity by indication
PART 09: MARKET SEGMENTATION BY DRUG CLASS
• Segmentation by drug class
PART 10: CUSTOMER LANDSCAPE
PART 11: REGIONAL LANDSCAPE
• Geographical segmentation
• Regional comparison
• Americas – Market size and forecast 2017-2022
• EMEA – Market size and forecast 2017-2022
• APAC – Market size and forecast 2017-2022
• Market opportunity
PART 12: DECISION FRAMEWORK
PART 13: DRIVERS AND CHALLENGES
• Market drivers
• Market challenges
PART 14: MARKET TRENDS
PART 15: VENDOR LANDSCAPE
• Overview
• Landscape disruption
PART 16: VENDOR ANALYSIS
• Vendors covered
• Vendor classification
• Market positioning of vendors
• ALLERGAN
• Biogen
• Novartis
• Teva Pharmaceutical
PART 17: APPENDIX
• List of abbreviations

Exhibit 01: Parent market
Exhibit 02: Global CNS therapeutics market
Exhibit 03: Market characteristics
Exhibit 04: Market segments
Exhibit 05: Pipeline drugs under Phase III development
Exhibit 06: Market definition – Inclusions and exclusions checklist
Exhibit 07: Market size 2017
Exhibit 08: Validation techniques employed for market sizing 2017
Exhibit 09: Global neurodegenerative diseases therapeutics market – Market size and forecast 2017-2022 ($ bn)
Exhibit 10: Global neurodegenerative diseases therapeutics market – Year over year growth 2018-2022 (%)
Exhibit 11: Five forces analysis 2017
Exhibit 12: Five forces analysis 2022
Exhibit 13: Bargaining power of buyers
Exhibit 14: Bargaining power of suppliers
Exhibit 15: Threat of new entrants
Exhibit 16: Threat of substitutes
Exhibit 17: Threat of rivalry
Exhibit 18: Market condition – Five forces 2017
Exhibit 19: Global neurodegenerative diseases therapeutics market by indication – Market share 2017-2022 (%)
Exhibit 20: Comparison by indication
Exhibit 21: Global neurodegenerative diseases therapeutics market by multiple sclerosis – Market size and forecast 2017-2022 ($ bn)
Exhibit 22: Global neurodegenerative diseases therapeutics market by multiple sclerosis – Year over year growth 2018-2022 (%)
Exhibit 23: Global neurodegenerative diseases therapeutics market by others – Market size and forecast 2017-2022 ($ bn)
Exhibit 24: Global neurodegenerative diseases therapeutics market by others – Year over year growth 2018-2022 (%)
Exhibit 25: Global neurodegenerative diseases therapeutics market by Alzheimer’s disease – Market size and forecast 2017-2022 ($ bn)
Exhibit 26: Global neurodegenerative diseases therapeutics market by Alzheimer’s disease – Year over year growth 2018-2022 (%)
Exhibit 27: Global neurodegenerative diseases therapeutics market by Parkinson’s disease – Market size and forecast 2017-2022 ($ bn)
Exhibit 28: Global neurodegenerative diseases therapeutics market by Parkinson’s disease – Year over year growth 2018-2022 (%)
Exhibit 29: Global neurodegenerative diseases therapeutics market by Huntington’s disease – Market size and forecast 2017-2022 ($ mn)
Exhibit 30: Global neurodegenerative diseases therapeutics market by Huntington’s disease – Year over year growth 2018-2022 (%)
Exhibit 31: Market opportunity by indication
Exhibit 32: Customer landscape
Exhibit 33: Global neurodegenerative diseases therapeutics market by region – Market share 2017-2022 (%)
Exhibit 34: Regional comparison
Exhibit 35: Neurodegenerative diseases therapeutics market in Americas – Market size and forecast 2017-2022 ($ bn)
Exhibit 36: Neurodegenerative diseases therapeutics market in Americas – Year over year growth 2018-2022 (%)
Exhibit 37: Top 3 countries in Americas
Exhibit 38: Neurodegenerative diseases therapeutics market in EMEA – Market size and forecast 2017-2022 ($ bn)
Exhibit 39: Neurodegenerative diseases therapeutics market in EMEA – Year over year growth 2018-2022 (%)
Exhibit 40: Top 3 countries in EMEA
Exhibit 41: Neurodegenerative diseases therapeutics market in APAC – Market size and forecast 2017-2022 ($ bn)
Exhibit 42: Neurodegenerative diseases therapeutics market in APAC – Year over year growth 2018-2022 (%)
Exhibit 43: Top 3 countries in APAC
Exhibit 44: Market opportunity
Exhibit 45: Late-stage pipeline for different neurogenerative diseases during 2017-2018
Exhibit 46: Some patent expiries of neurodegenerative diseases in US
Exhibit 47: Some drug failures for neurodegenerative diseases in clinical trials in 2017-2018
Exhibit 48: Vendor landscape
Exhibit 49: Landscape disruption
Exhibit 50: Vendors covered
Exhibit 51: Vendor classification
Exhibit 52: Market positioning of vendors
Exhibit 53: Vendor overview
Exhibit 54: ALLERGAN – Business segments
Exhibit 55: ALLERGAN – Organizational developments
Exhibit 56: ALLERGAN – Geographic focus
Exhibit 57: ALLERGAN – Segment focus
Exhibit 58: ALLERGAN – Key offerings
Exhibit 59: Vendor overview
Exhibit 60: Biogen – Business segments
Exhibit 61: Biogen – Organizational developments
Exhibit 62: Biogen – Geographic focus
Exhibit 63: Biogen – Key offerings
Exhibit 64: Vendor overview
Exhibit 65: Novartis – Business segments
Exhibit 66: Novartis – Organizational developments
Exhibit 67: Novartis – Geographic focus
Exhibit 68: Novartis – Segment focus
Exhibit 69: Novartis – Key offerings
Exhibit 70: Vendor overview
Exhibit 71: Teva Pharmaceutical – Business segments
Exhibit 72: Teva Pharmaceutical – Organizational developments
Exhibit 73: Teva Pharmaceutical – Geographic focus
Exhibit 74: Teva Pharmaceutical – Segment focus
Exhibit 75: Teva Pharmaceutical – Key offerings



LINEで送る
Share on LinkedIn
このエントリーをはてなブックマークに追加
Bookmark this on BuzzURL
Bookmark this on Yahoo Bookmark